bbc semaglutide Popular weight-loss drugs like Ozempic and Wegovy have become cheaper in India. , Last week, the patent on - the molecule behind both drugs Weight-loss injections promise rapid results

Head-to-Head Comparison: Key Metrics Semaglutide: MW 4113.58 Da | Selective GLP-1 RA | Injectable (weekly) or oral (daily with SNAC) | Mean weight loss 14.9% (STEP 1) | FDA-approved 2021 (obesity) Tirzepatide: MW ~4813.45 Da | Dual GLP-1/GIP | Injectable (weekly) | Mean weight loss 22.5% (SURMOUNT-1) | FDA-approved 2023 (obesity) Retatrutide: MW ~4500 Da | Triple GLP-1/GIP/Glucagon | Injectable (weekly) | Mean weight loss 28.7% (TRIUMPH-4 Phase 3) | Phase 3 as of 2026 Orforglipron: MW 541.65 Da | Selective GLP-1 (non-peptide) | Oral (daily, no food restriction) | Mean weight loss ~14.7% (Phase 3) | FDA-approved April 2026 Receptor Selectivity and Mechanism Differences The four compounds represent a spectrum from single-target to multi-target pharmacology

Researchers must avoid any form of bodily introduction into humans or animals, as the law strictly prohibits it

Beyond skin manifestations, psoriasis correlates with psychological impacts and systemic conditions including cardiovascular disease and psoriatic arthritis

This combination addresses both local gut tissue repair and overall inflammatory burden